707 related articles for article (PubMed ID: 27566954)
1. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
[TBL] [Abstract][Full Text] [Related]
4. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
[TBL] [Abstract][Full Text] [Related]
6. 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.
Turashvili G; Chou JF; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
Breast Cancer Res Treat; 2017 Nov; 166(1):69-76. PubMed ID: 28702894
[TBL] [Abstract][Full Text] [Related]
7. A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment.
Du F; Yuan P; Zhao ZT; Yang Z; Wang T; Zhao JD; Luo Y; Ma F; Wang JY; Fan Y; Cai RG; Zhang P; Li Q; Song YM; Xu BH
Sci Rep; 2016 Sep; 6():33825. PubMed ID: 27650797
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
9. Recurrence prediction using microRNA expression in hormone receptor positive breast cancer during tamoxifen treatment.
Kim C; Go EJ; Kim A
Biomarkers; 2018 Dec; 23(8):804-811. PubMed ID: 30010434
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
11. Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients.
Ota D; Mimori K; Yokobori T; Iwatsuki M; Kataoka A; Masuda N; Ishii H; Ohno S; Mori M
Int J Oncol; 2011 Apr; 38(4):955-62. PubMed ID: 21271219
[TBL] [Abstract][Full Text] [Related]
12. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
13. A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer.
Chen X; Wang YW; Zhu WJ; Li Y; Liu L; Yin G; Gao P
Hum Pathol; 2018 Jun; 76():122-132. PubMed ID: 29555574
[TBL] [Abstract][Full Text] [Related]
14. Expression of Estrogen Receptor- and Progesterone Receptor-Regulating MicroRNAs in Breast Cancer.
Kalinina T; Kononchuk V; Alekseenok E; Obukhova D; Sidorov S; Strunkin D; Gulyaeva L
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33923732
[TBL] [Abstract][Full Text] [Related]
15. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA regulation of progesterone receptor in breast cancer.
Gilam A; Shai A; Ashkenazi I; Sarid LA; Drobot A; Bickel A; Shomron N
Oncotarget; 2017 Apr; 8(16):25963-25976. PubMed ID: 28404930
[TBL] [Abstract][Full Text] [Related]
17. Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study.
Zeng Y; Li Q; Qin T; Li S; Jin L; Wu J; Chen K; Deng H; Rao N; Liu Q; Su F; Jia W; Yao H
Anticancer Res; 2017 Aug; 37(8):4539-4547. PubMed ID: 28739750
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
19. Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.
Duchnowska R; Jassem J; Goswami CP; Dundar M; Gökmen-Polar Y; Li L; Woditschka S; Biernat W; Sosińska-Mielcarek K; Czartoryska-Arłukowicz B; Radecka B; Tomasevic Z; Stępniak P; Wojdan K; Sledge GW; Steeg PS; Badve S
J Neurooncol; 2015 Mar; 122(1):205-16. PubMed ID: 25559688
[TBL] [Abstract][Full Text] [Related]
20. Essential role of miR-200c in regulating self-renewal of breast cancer stem cells and their counterparts of mammary epithelium.
Feng ZM; Qiu J; Chen XW; Liao RX; Liao XY; Zhang LP; Chen X; Li Y; Chen ZT; Sun JG
BMC Cancer; 2015 Sep; 15():645. PubMed ID: 26400441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
